Elena777 ☆ Belarus, 20190909 21:34 (1541 d 09:56 ago) Posting: # 20564 Views: 8,779 

Dear all, I would be pleased to get your opinion on the following. We are planning to conduct several BE studies with adaptive design using the drugs with uncertain intraCV. We have decided to use method C described by Potvin and included the description of the model C in the protocols (the same as in the corresponding scheme presented in Potvin's article). But it seems it's not enough.
Post number 20,000. [Helmut] 
ElMaestro ★★★ Denmark, 20190909 23:39 (1541 d 07:51 ago) @ Elena777 Posting: # 20565 Views: 8,215 

Hello Elena777, ❝ 1. Should we include the information that evaluation after stage 1 completion should be performed assuming GMR=0.95? I would do so. ❝ 2. Should we describe the maximum number of subjects who can be included in whole or in stage 2? I would only put a cap on it if you can refer to simulations having done exactly so (having done so in exactly your way of capping). ❝ 3. Any other information that should be clearly stated in order to be accurate and to satisfy regulatory authorities? Exact decision tree, and exact values for alphas, desired power level, and power being calculated using GMR=0.95. ❝ 4. What if BE criteria are met after stage 1, but estimated power is too low (e.g. 30%)? "Too low"? It is not a crime to be lucky. I don't see any issue. Regulators are generally not afraid of low power after results become available. This forum is a paradise for grumpy old men being adverse to posthoc power. I used be to a reasonably happy, cheerful bloke, but then I got a profile here and quickly I went very sour if not outright angry. I blend in nicely, I think?!? — Pass or fail! ElMaestro 
Helmut ★★★ Vienna, Austria, 20190910 01:27 (1541 d 06:03 ago) @ ElMaestro Posting: # 20567 Views: 8,108 

Hi ElMaestro, ❝ ❝ 1. Should we include the information that evaluation after stage 1 completion should be performed assuming GMR=0.95? ❝ ❝ I would do so. So would I. ❝ ❝ 2. Should we describe the maximum number of subjects who can be included in whole or in stage 2? ❝ ❝ I would only put a cap on it if you can refer to simulations having done exactly so (having done so in exactly your way of capping). From a regulatory perspective this is not necessary. Any futility rule (like max. n_{2}) decreases the chance to show BE if compared to a published method without one. Hence, if the type I error was controlled in a method without a futility rule, the TIE will always be lower with a futility rule. However, if a futility rule is too strict, you may shoot yourself in the foot since power might be compromised. To check that, sim’s are a good idea indeed. ❝ ❝ 3. Any other information that should be clearly stated in order to be accurate and to satisfy regulatory authorities? ❝ ❝ Exact decision tree, and exact values for alphas, desired power level, and power being calculated using GMR=0.95. Yep. ❝ ❝ 4. What if BE criteria are met after stage 1, but estimated power is too low (e.g. 30%)? ❝ ❝ It is not a crime to be lucky. Absolutely. As one of the grumpy old men: Forget power, doesn’t matter. — Diftor heh smusma 🖖🏼 Довге життя Україна! _{} Helmut Schütz The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes 
Ohlbe ★★★ France, 20190910 12:27 (1540 d 19:03 ago) @ ElMaestro Posting: # 20570 Views: 8,173 

Dear ElMaestro, [off topic] ❝ This forum is a paradise for grumpy old men being adverse to posthoc power. Hey, I'm not old ! [/off topic] — Regards Ohlbe 
Helmut ★★★ Vienna, Austria, 20190910 01:17 (1541 d 06:13 ago) @ Elena777 Posting: # 20566 Views: 8,313 

Hi Elena, ❝ We are planning to conduct several BE studies with adaptive design using the drugs with uncertain intraCV. We have decided to use method C described by Potvin … Whether Potvin’s Method C will be accepted depends on the jurisdiction you are bound to.^{a,b} More information please.
— Diftor heh smusma 🖖🏼 Довге життя Україна! _{} Helmut Schütz The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes 
Elena777 ☆ Belarus, 20190911 22:24 (1539 d 09:07 ago) @ Helmut Posting: # 20587 Views: 7,984 

Dear Helmut and ElMaestro, Thank you very much for responding me shortly. We are planning to submit applications in Belarus (the country I`m from) and in Russia. Hope method C will be OK for them. Another 2 questions:

Helmut ★★★ Vienna, Austria, 20190912 03:31 (1539 d 03:59 ago) @ Elena777 Posting: # 20589 Views: 8,159 

Hi Elena, ❝ We are planning to submit applications in Belarus (the country I`m from) and in Russia. Hope method C will be OK for them. THX for the information. Sections 97/98 of the EEU regulations are a 1:1 translation of the corresponding section about TSDs in the EMA’s BEGL. It is difficult to predict how regulators of the EEU interpret their own guideline. Maybe other members from Belarus (4) and Russia (21) can share their experiences. My ranking (not based on scientific value but on likelihood of acceptance) in the following. To explore the empiric type I error (TIE) I recommend functions of the package Power2Stage with 1 mio simulations at theta0=1.25 . When I give locations of the maximum TIE it is based on a much narrower grid than in the publications (n_{1} 12…72, step size 2 and CV 10…80%, step size 2%).[list=1][*]Potvin et al. “Method B”^{ 1}According to the wording of the GL “… both analyses [should be] conducted at adjusted significance levels …” Maximum inflation of the TIE 0.0490 (with n_{1} 12 and CV 24%). Hence, the adjusted α 0.0294 is conservative. power.tsd(method="B", alpha=c(0.0294, 0.0294), CV=0.24, However, no inflation of the TIE with a slightly more liberal α 0.0302. power.tsd(method="B", alpha=c(0.0302, 0.0302), CV=0.24, [*]Karalis “TSD2”^{ 2} Futility rule for the total sample size of 150. No inflation of the TIE. Compare with the Potvin B above (0.048762): power.tsd.KM(method="B", alpha=c(0.0294, 0.0294), CV=0.24, However, power may be negatively affected^{ 3,4} and total sample sizes sometimes even larger. Comparison: CV < 0.25 [*]Karalis “TSD1”^{ 2} As above but decision scheme similar to Potvin C and α 0.0280. power.tsd.KM(method="C", alpha=c(0.0280, 0.0280), CV=0.22, Compare to the TIE below. [*]Potvin et al. “Method C”^{ 1} Ignoring the sentence of the GL mentioned at #1 above and concentrating on “… there are many acceptable alternatives and the choice of how much alpha to spend at the interim analysis is at the company’s discretion.” With the adjusted α 0.0294 there is a maximum inflation of the TIE of 0.0514 (with n_{1} 12 and CV 22%). power.tsd(method="C", alpha=c(0.0294, 0.0294), CV=0.22, However, there is no inflation of the TIE for any CV and n_{1} ≥18. If you want to go with Method C, I suggest a more conservative adjusted α 0.0280. power.tsd(method="C", alpha=c(0.0280, 0.0280), CV=0.22, [*]Xu et al., “Method E”, “Method F”^{ 5} More powerful than the original methods of the same group of authors since two CVranges are considered. “Method E” is an extension of “Method B” and “Method F” of “Method C”. Both have different alphas in the stages and a futility rule based on the 90% CI and a maximum sample size (though not as futility). Slight misspecification of the CV (say, you assumed CV 25% and the CV turns out to be 35%) still controls the TIE.
power.tsd.fC(method="B", alpha=c(0.0249, 0.0363), CV=0.30, n1=18, [*]Maurer et al.^{ 6} The only approach not based on simulations and seemingly preferred by the EMA. That’s the most flexible method because you can specify futility rules on the CI, achievable total power, maximum total sample size. Furthermore, you can base the decision to proceed to the second stage on the PE observed in the first stage (OK, this is supported by the functions of Power2Stage as well but not in the published methods – you would have to perform own simulations). Example: power.tsd.in(CV=0.24, n1=12, theta0=1.25, fCrit="No", Let us compare the method with data of Example 2 given by Potvin et al. Note that in this method you perform separate ANOVAs, one in the interim and one in the final analysis. In Example 2 we had 12 subjects in stage 1 and with both methods a second stage with 8 subjects. The final PE was 101.45% with a 94.12% CI of 88.45–116.38%. I switched off futility criteria and kept all other defaults. interim.tsd.in(GMR1=1.0876, CV1=0.18213, n1=12, Similar outcome. Not BE and second stage with 8 subjects. final.tsd.in(GMR1=1.0876, CV1=0.18213, n1=12, Passed BE as well. PE 101.35 with a 94.73% CI of 87.69–117.36%. Acceptance in Belarus & Russia – no idea. Might well be that their experts never have seen such a study before.[/list]Personally (‼) I would rank the methods[list=1][*]Maurer et al. [*]Xu et al. “Method F” [*]Xu et al. “Method E” [*]Potvin et al. “Method C” (modified α 0.0280) [*]Potvin et al. “Method B” (modified α 0.0302) [*]Potvin et al. “Method C” (original α 0.0294) [*]Potvin et al. “Method B” (original α 0.0294) [*]Karalis “TSD1” [*]Karalis “TSD2”[/list]Maybe the original “Method C” is risky when you proceed to the second stage (all my accepted studies were BE already in stage 1 and I have seen nasty deficiency letters in the past). ❝ Another 2 questions: ❝ 1. Is it a good idea to add the statement that, in case of conducting stage 2, data from both stages will be pooled by default, without evaluation of differences between stages? If you performed the second stage, it’s mandatory to pool the data. None of the methods contains any kind of test between stages. Furthermore, a formulationbystage interaction term in the model is considered nonsense in the EMA’s Q&A. ❝ 2. Is there any established minimum for a number of subjects that should be included in stage 2 (e.g. at least 2, or at least 1 for each sequence (TR/RT))? Nothing in the guidelines, but mentioned in the EMA’s Q&A document. However, that’s superfluous. If you perform a sample size estimation, in all software the minimum stage 2 sample size will be 2 anyhow (if odd, rounded up to the next even to obtain balanced sequences). In the functions of Power2Stage you can used the argument min.n2=2 and will never see any difference.Only if you are a nerd, read the next paragraph. The conventional sample size estimation does not take the stageterm in the final analysis into account. If you prefer to use braces with suspenders, use the function In #5 the minimum is 4 because you perform a separate ANOVA in the second stage. One word of caution: If you have a nasty drug (dropouts due to AEs) take care that you don’t end up with <3 subjects – otherwise the ANOVA would not be possible. In designing a study I recommend to call the functions with the arguments theta0 and CV , which are your best guesses. Don’t confuse that with the argument GMR , which is fixed in most methods. Then you get an impression what might happen (chance to show BE in the first stage, probability to proceed to stage 2, average & range of total sample sizes…). n_{1} which is ~80% of a fixed sample design is a good compromise between chances to show BE in the first stage whilst keeping overall power. Example of finding a suitable futility rule of the total sample size:CV < 0.25 A futility rule of 48 looks good. Let’s explore the details: Power2Stage::power.tsd(CV=CV, n1=n1, Nmax=48) Not that bad. However, futility rules can be counterproductive because you have to come up with a “best guess” CV – which is actually against the “sprit” of TSDs. Homework: Power2Stage::power.tsd(CV=0.30, n1=24, Nmax=48) As ElMaestro wrote above you have to perform own simulations if you are outside the published methods (GMR, target power, n_{1}/CVgrid, futility rules). My basic algorithm is outlined by Molins et al.^{ 7} A final reminder: In the sample size estimation use the fixed GMR (not the observed one), unless the method allows that. [list=1][*]Potvin D, DiLiberti CE, Hauck WW, Parr AF, Schuirmann DJ, Smith RA. Sequential design approaches for bioequivalence studies with crossover designs. Pharm Stat. 2008; 7(4): 245–62. doi:10.1002/pst.294. [*]Karalis V. The role of the upper sample size limit in twostage bioequivalence designs. Int J Pharm. 2013; 456: 87–94. doi:j.ijpharm.2013.08.013. [*]Fuglsang A. Futility Rules in Bioequivalence Trials with Sequential Designs. AAPS J. 2014; 16(1): 79–82. doi:10.1208/s1224801395400. [*]Schütz H. Twostage designs in bioequivalence trials. Eur J Clin Pharmacol. 2015; 71(3): 271–81. doi:10.1007/s0022801518062. [*]Xu J, Audet C, DiLiberti CE, Hauck WW, Montague TH, Parr TH, Potvin D, Schuirmann DJ. Optimal adaptive sequential designs for crossover bioequivalence studies. Pharm Stat. 2016; 15(1): 15–27. doi:10.1002/pst.1721. [*]Maurer W, Jones B, Chen Y. Controlling the type 1 error rate in twostage sequential designs when testing for average bioequivalence. Stat Med. 2018; 37(10): 1587–607. doi:10.1002/sim.7614. [*]Molins E, Cobo E, Ocaña J. Twostage designs versus European scaled average designs in bioequivalence studies for highly variable drugs: Which to choose? Stat Med. 2017; 36(30): 4777–88. doi:10.1002/sim.7452.[/list] — Diftor heh smusma 🖖🏼 Довге життя Україна! _{} Helmut Schütz The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes 
Astea ★★ Russia, 20190914 16:56 (1536 d 14:34 ago) @ Helmut Posting: # 20597 Views: 7,819 

Dear all! Elena777, I guess I misunderstood something. Did you mean aposteriory power or interim power? If interim is 30% go to the next step by the decision tree. ❝ It is difficult to predict how regulators of the EEU interpret their own guideline Helmut, what was the final conclusions on the post? Are there any suggestions on how to deal with two metrics in adaptive trials? For example: a). Let us consider Type II design: first step  estimated power is less than target (80%) for C_{max} and more than target for AUC, besides 90%CI for AUC is OK. 1). We calculate 100(12α_{adj}) CI for C_{max}, should we also do it for AUC? It can fail. 2). Suppose further we go to the 2^{nd} stage. Should we use data from the 2^{nd} stage to estimate CI for AUC the second time? If yes, it possibly can fail, if not  how to explain the fact that we do not use the data? Another example: b). First step  estimated power is less than target (80%) for both metrics and adjusted level CI is outside the range. Should we use the largest observed CV to calculate the total sample size? Would the study be overpowered for the second PK metric? Would it affect the TIE? To conclude: what is the best strategy to follow in this situation in order to avoid inflation of the TIE and the loss of power? (Some mad idea: is it possible to make some hybrid monster to combine both C_{max} and AUC in the same test for adaptive designs? Something like C_{max}/AUC but with more powerful reflection of the situations (I dealt with a plenty of studies (BE and not proven BE) with C_{max}/AUC as an additional metric, only once it was outside the range) ❝ Furthermore, a formulationbystage interaction term in the model is considered nonsense in the EMA’s Q&A. What ANOVA model should be used for the second stage? By the way, what about the code on R for the full decision tree? — "Being in minority, even a minority of one, did not make you mad" 
Helmut ★★★ Vienna, Austria, 20190916 13:50 (1534 d 17:40 ago) @ Astea Posting: # 20598 Views: 7,908 

Hi Nastia, ❝ Helmut, what was the final conclusions on the post? I was wrong and we shouldn’t worry. See Detlew’s simulations. ❝ Are there any suggestions on how to deal with two metrics in adaptive trials? ❝ For example: a). Let us consider Type II design: first step  estimated power is less than target (80%) for C_{max} and more than target for AUC, besides 90%CI for AUC is OK. ❝ 1). We calculate 100(12α_{adj}) CI for C_{max}, should we also do it for AUC? It can fail. ❝ 2). Suppose further we go to the 2^{nd} stage. Should we use data from the 2^{nd} stage to estimate CI for AUC the second time? If yes, it possibly can fail, if not  how to explain the fact that we do not use the data? Think about how we design a fixed sample design. Always based on the metric with the higher CV. I would go with your 2). How likely is it that AUC (which passed already in the first stage) will fail in the second? Let’s consider the example of the other post. I assumed the best, i.e., all studies in the ‘type II’ design passed with α 0.05. Now:
❝ Another example: b). First step  estimated power is less than target (80%) for both metrics and adjusted level CI is outside the range. Should we use the largest observed CV to calculate the total sample size? Yes. ❝ Would the study be overpowered for the second PK metric? Would it affect the TIE? According to Detlew’s simulations, no. Given, only ‘type I’ implemented which is more conservative anyhow.
❝ To conclude: what is the best strategy to follow in this situation in order to avoid inflation of the TIE and the loss of power? Estimate the sample size based on the metric with the higher CV. No inflation of the TIE and a gain in power for the other metric. ❝ (Some mad idea: is it possible to make some hybrid monster to combine both C_{max} and AUC in the same test for adaptive designs? Take some Schützomycin? ❝ Something like C_{max}/AUC but with more powerful reflection of the situations (I dealt with a plenty of studies (BE and not proven BE) with C_{max}/AUC as an additional metric, only once it was outside the range) As expected. C_{max}/AUC is generally less variable than C_{max}. ❝ ❝ Furthermore, a formulationbystage interaction term in the model is considered nonsense in the EMA’s Q&A. ❝ ❝ What ANOVA model should be used for the second stage? According to the Q&A: stage, sequence, sequence × stage, subject(sequence × stage), period(stage), treatment. As usual for the EMA, all effects fixed and the nested term subject(sequence × stage) superfluous.The simple model stage, sequence, sequence × stage, subject, period(stage), treatment. gives exactly the same result.I once received a deficiency letter for a ‘type 2’ study passing in the first stage (α 0.05!) where I dared to model subjects as a random effect… Interesting that there were no questions to use an adjusted α (would have passed as well but I followed my SAP which was approved by the BfArM and for “educational reasons” I didn’t show the adjusted CI). ❝ By the way, what about the code on R for the full decision tree? Ask Detlew or inspect the sources of power.tsd() and power.tsd.2m() . — Diftor heh smusma 🖖🏼 Довге життя Україна! _{} Helmut Schütz The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes 
Astea ★★ Russia, 20190916 20:28 (1534 d 11:02 ago) @ Helmut Posting: # 20599 Views: 7,908 

Dear Helmut! ❝ I was wrong and we shouldn’t worry. See Detlew’s simulations. That's good. Sorry, I didn't realized it at first. ❝ How likely is it that AUC (which passed already in the first stage) will fail in the second? Thank you for the example! I've puzzled whether it will be reproduced for other cases. Let us consider the situation when CV of C_{max} and AUC are very close to each other, like 21% and 20%, and for the first stage the number of subjects (n_{1}=20) was sufficient for AUC, but not for C_{max}. Calculation shows that even then the power for AUC for the second stage would be always enough.
❝ Take some Schützomycin? Did you patent that? I gonna make a generic ❝ According to the Q&A: stage, sequence, sequence × stage, subject(sequence × stage), period(stage), treatment. Are there any documents to refer which mention this model (excepting the answer on the EMA's web page?) ❝ Ask Detlew or inspect the sources of Ok, need more tea to dive to the source... — "Being in minority, even a minority of one, did not make you mad" 
Helmut ★★★ Vienna, Austria, 20190917 14:27 (1533 d 17:03 ago) @ Astea Posting: # 20606 Views: 7,616 

Hi Nastia, ❝ Let us consider the situation when CV of C_{max} and AUC are very close to each other, like 21% and 20%, and for the first stage the number of subjects (n_{1}=20) was sufficient for AUC, but not for C_{max}. ❝ […] even then the power for AUC for the second stage would be always enough. […] Wow, you are a master of condensed Rcode! Here my version:
❝ ❝ Take some Schützomycin? ❝ ❝ Did you patent that? I gonna make a generic Not mine. It was mentioned for the first time by ElMaestro back in 2010: ❝ ❝ Let's say we want to develop a generic of Schützomycin. The product is available in one strength, posology is 1 tablet daily. […] Schützomycin is a nice drug with little safety concern. My claim seems to be unfounded. ❝ ❝ According to the Q&A: stage, sequence, sequence × stage, subject(sequence × stage), period(stage), treatment. ❝ Are there any documents to refer which mention this model (excepting the answer on the EMA's web page?) Made up out of thin air by the EMA. To quote myself^{1} In none of the published procedures, a test for poolability was part of the simulations. Although statistical tests could be constructed comparing variances of stages, their precision is poor in such designs and should be applied with caution. Nonetheless, in 2013, the European Medicines Agency introduced an additional term sequence×stage to the statistical model. Since both sequence and stage are betweensubject effects, the residual error (hence, the CI) should not be affected – which was recently demonstrated.^{2} Excerpt^{2} Special emphasis was also given to the significance (P value) of the additional term ‘sequence × stage’ used in the ANOVA model proposed by EMA. […]
You don’t have to be a rocket scientist to understand that. Why the EMA introduced it, remains a mystery. Maybe influenced by GarcíaArieta and Gordon?^{3} A term for the stage should be included in the ANOVA model. However, the guideline does not clarify what the consequence should be if it is statistically significant. In principle, the data sets of both stages could not be combined. Well, stage is already a factor in all published methods (didn’t they read them?). Concerning “poolability” see above. Reminds me on Grizzle’s nonsense for crossovers “if the sequenceeffect is significant, analyze data of the first period as a parallel design”.
— Diftor heh smusma 🖖🏼 Довге життя Україна! _{} Helmut Schütz The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes 
Astea ★★ Russia, 20190917 22:34 (1533 d 08:56 ago) @ Helmut Posting: # 20607 Views: 7,544 

Dear Helmut! Thanks for enlighting the dark story of ANOVA model! ❝ Is this what you mean? Yes, my code gives power.1 for delta 0.01, but without limitations of minimum 12 subjects. Note that for CV.lo≤14% the 2nd stage would not be started, cause power for 12 is already more than 80%. ❝ My claim seems to be unfounded. 
Helmut ★★★ Vienna, Austria, 20190918 14:12 (1532 d 17:18 ago) @ Astea Posting: # 20610 Views: 7,462 

Hi Nastia, ❝ Oh, it turns out that Schützomycin could be a secret ingredient of Azazello'scream? Possible. THX for pointing to The Master and Margarita. I’ve read it when I was (sweet?) little sixteen. — Diftor heh smusma 🖖🏼 Довге життя Україна! _{} Helmut Schütz The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes 
Elena777 ☆ Belarus, 20190916 21:48 (1534 d 09:43 ago) @ Helmut Posting: # 20601 Views: 7,644 

Dear Helmut, Still need some clarifications on the question from Astea: ❝ a) first step  estimated power is less than target (80%) for C_{max} and more than target for AUC, besides 90%CI for AUC is OK. To be in compliance with method C of Potvin, we recalculate CI for Cmax with α=0,0294. Let`s assume that BE criterion for Cmax is met after this step. Should we also recalculate CI for AUC with α=0,0294? Otherwise, finally we will have the following in a CSR: BE criterion was met for AUC using α=0,05 (90%CI) and BE criterion was met for Cmax using α=0,0294 (94,12% CI). Does it look OK? 
Helmut ★★★ Vienna, Austria, 20190917 01:30 (1534 d 06:01 ago) @ Elena777 Posting: # 20603 Views: 7,682 

Hi Elena, ❝ To be in compliance with method C of Potvin, we recalculate CI for Cmax with α=0,0294. Let`s assume that BE criterion for Cmax is met after this step. […] Otherwise, finally we will have the following in a CSR: BE criterion was met for AUC using α=0,05 (90%CI) and BE criterion was met for Cmax using α=0,0294 (94,12% CI). Does it look OK? Absolutely. The ideas behind the different alphas in Potvin C are:
❝ Should we also recalculate CI for AUC with α=0,0294? You could but please only “at home”. That’s against the method and what you should have laid down in the protocol. See the end of this post. My study would have passed with the adjusted α as well. But what if not? See this bizarre case study. If the sponsor would have known before that the agency will not accept Method C, they would have planned for Method B, initiated a second stage with 6 (six!) subjects and happily walked away. Stupid. What will you do with your ”homework”?
I recommended it for years. Well, no more. IMHO, the small gain in power claimed by the authors is not worth the troubles:
— Diftor heh smusma 🖖🏼 Довге життя Україна! _{} Helmut Schütz The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes 
Mikalai ★ Belarus, 20190918 18:56 (1532 d 12:35 ago) @ Helmut Posting: # 20611 Views: 7,416 

Dear Helmut, ❝ 1. If interim power is <80%, your assumptions about the CV were not correct. Assess the study with the adjusted α 0.0294. ❝ a. If you pass, stop. What prevents us from evaluating the bioequivalence at αlevel of 5% as the first step, and if we pass the bioequivalence criteria, we stop the trial. If we fail, we then evaluate the power. If power is more than 80% for the failed parameter, we stop the trial and we are done. If power is less than 80% for the failed parameter, then we go the next stage and adust αlevel correspondingly to preserve overall αlevel at 0,5. Of course, this should be written in the protocol and is a deviation, maybe a big one, from Potvin C method. Regards, Mikalai 
Helmut ★★★ Vienna, Austria, 20190918 19:09 (1532 d 12:22 ago) @ Mikalai Posting: # 20612 Views: 7,459 

Dear Mikalai, ❝ What prevents us from evaluating the bioequivalence at αlevel of 5% as the first step, and if we pass the bioequivalence criteria, we stop the trial. If we fail, we then evaluate the power. If power is more than 80% for the failed parameter, we stop the trial and we are done. If power is less than 80% for the failed parameter, then we go the next stage and adust αlevel correspondingly to preserve overall αlevel at 0,5. Of course, this should be written in the protocol and is a deviation, maybe a big one, from Potvin C method. That’s more or less a hybrid of Method C (where you asses power first) and Method B (where you assess power after). You are free to develop such a method but have to validate it (i.e., find a suitable adjusted α which controls the type I error in every possible combination of n_{1}/CV). — Diftor heh smusma 🖖🏼 Довге життя Україна! _{} Helmut Schütz The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes 
Elena777 ☆ Belarus, 20190919 10:34 (1531 d 20:56 ago) @ Helmut Posting: # 20615 Views: 7,426 

Dear Helmut, I`m sorry for being persistent on the topic. ❝ »First step  estimated power is less than target (80%) for Cmax and more than target for AUC, 90%CI for AUC is OK. To be in compliance with method C of Potvin, we recalculate CI for Cmax with α=0,0294. And BE criterion for Cmax is met after this step. Finally we will have the following in a CSR: BE criterion was met for AUC using α=0,05 (90%CI) and BE criterion was met for Cmax using α=0,0294 (94,12% CI). Does it look OK? ❝ ❝ Absolutely. The ideas behind the different alphas in Potvin C are:
❝ To be completely sure that I understood you in a proper way, the final question is: First step  estimated power is less than target (80%) for Cmax and more than target for AUCt. 90%CI for AUCt is OK. As per method C of Potvin, we recalculate CI for Cmax with α=0,0294. And BE criterion for Cmax is NOT met after this step. Then we calculate CVintra for Cmax and proceed with the second stage. What combined data should be evaluated after stage 2 completion: ONLY for Cmax or for Cmax and AUCt? 
Helmut ★★★ Vienna, Austria, 20190919 17:16 (1531 d 14:14 ago) @ Elena777 Posting: # 20617 Views: 7,294 

Hi Elena, ❝ […] What combined data should be evaluated after stage 2 completion: ONLY for Cmax or for Cmax and AUCt? Whatever drives the second stage, you have to use all data (C_{max} and AUC). Whilst from a statistical perspective there would be no need to assess AUC (already BE in the first stage) no regulator would accept that. Once you dosed subjects, you have to use the data. No way out. — Diftor heh smusma 🖖🏼 Довге життя Україна! _{} Helmut Schütz The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes 
Elena777 ☆ Belarus, 20190919 17:27 (1531 d 14:04 ago) @ Helmut Posting: # 20618 Views: 7,436 

Dear Helmut, Thank you for responding me shortly. This is our first experience in conducting such studies, so we are quite excited. 
Helmut ★★★ Vienna, Austria, 20190919 18:15 (1531 d 13:15 ago) @ Elena777 Posting: # 20622 Views: 7,324 

Hi Elena, ❝ This is our first experience in conducting such studies, so we are quite excited. Keep in mind that it might also be the first experience for the experts of the agencies you are aiming at. Possibly they have heard about the skeptic attitudes of European assessors towards ‘Method C’. Consider ‘Method B’ instead. See the end of this post for a comparison of power. What will it help to have (maybe) two subject less in the second stage and a study which is not accepted? I warned you. — Diftor heh smusma 🖖🏼 Довге життя Україна! _{} Helmut Schütz The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes 
Elena777 ☆ Belarus, 20190916 21:35 (1534 d 09:55 ago) @ Astea Posting: # 20600 Views: 7,655 

Dear Astea, ❝ Elena777, I guess I misunderstood something. Did you mean aposteriory power or interim power? If interim is 30% go to the next step by the decision tree. I meant interim power (power that we calculate after stage 1 completion). 
Astea ★★ Russia, 20190916 22:39 (1534 d 08:51 ago) @ Elena777 Posting: # 20602 Views: 7,750 

Dear Elena777! ❝ tree? I meant decision scheme (in graph theory mathematicians call "trees" undirected graphs). See also this message. ❝ To be in compliance with method C of Potvin, we recalculate CI for Cmax with α=0,0294. Let`s assume that BE criterion for Cmax is met after this step. Should we also recalculate CI for AUC with α=0,0294? Otherwise, finally we will have the following in a CSR: BE criterion was met for AUC using α=0,05 (90%CI) and BE criterion was met for Cmax using α=0,0294 (94,12% CI). Does it look OK? In this situation we still have to go to the next stage. As it was shown before the fail for AUC (if it has less variability than C_{max}) in the second stage is very unlikely. So it just doesn't matter what was CI for AUC after the first stage, the second stage for C_{max} should be crucial. — "Being in minority, even a minority of one, did not make you mad" 
Helmut ★★★ Vienna, Austria, 20190917 01:37 (1534 d 05:53 ago) @ Astea Posting: # 20604 Views: 7,694 

Hi Nastia, ❝ ❝ […] BE criterion was met for AUC using α=0,05 (90%CI) and BE criterion was met for Cmax using α=0,0294 (94,12% CI). Does it look OK? ❝ ❝ In this situation we still have to go to the next stage. Why (see above)? Both AUC and C_{max} passed already in the first stage. — Diftor heh smusma 🖖🏼 Довге життя Україна! _{} Helmut Schütz The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes 
Astea ★★ Russia, 20190917 08:14 (1533 d 23:16 ago) @ Helmut Posting: # 20605 Views: 7,740 

Dear Helmut and Elena777! ❝ Why (see above)? Both AUC and C_{max} passed already in the first stage. Oops, sorry . I was wrong (thought about the case of fail C_{max}). Thank you! 